Stock Scorer

Krystal Biotech, Inc. (KRYS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 50M 100M 150M Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 8.6M Q4 '23: 42.1M Q1 '24: 45.2M Q2 '24: 70.3M Q3 '24: 83.8M Q4 '24: 91.1M Q1 '25: 88.2M Q2 '25: 96M Q3 '25: 97.8M Q4 '25: 107.1M Q1 '26: 116.4M Q2 '26: 119.2M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -15.7M Q4 '21: -21.9M Q1 '22: -50.2M Q2 '22: -28.8M Q3 '22: -31.5M Q4 '22: -34.8M Q1 '23: -48.8M Q2 '23: -38M Q3 '23: -26M Q4 '23: 3.2M Q1 '24: -6.7M Q2 '24: 8.6M Q3 '24: 22.5M Q4 '24: 41.4M Q1 '25: 36.3M Q2 '25: 39.4M Q3 '25: 41.4M Q4 '25: 44.3M Q1 '26: 53.7M Q2 '26: 58.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-60M -30M 0 30M 60M 90M Q3 '21: -15.6M Q4 '21: -21.8M Q1 '22: -50M Q2 '22: -28.1M Q3 '22: -29.9M Q4 '22: -32.1M Q1 '23: -45.3M Q2 '23: -33.2M Q3 '23: 80.7M Q4 '23: 8.7M Q1 '24: 932K Q2 '24: 15.6M Q3 '24: 27.2M Q4 '24: 45.5M Q1 '25: 35.7M Q2 '25: 38.3M Q3 '25: 79.4M Q4 '25: 51.4M Q1 '26: 55.9M Q2 '26: 54.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -30M 0 30M 60M 90M Q3 '21: -7.3M Q4 '21: -20.9M Q1 '22: -15.5M Q2 '22: -43.1M Q3 '22: -19.7M Q4 '22: -22.3M Q1 '23: -26.2M Q2 '23: -34.2M Q3 '23: -21.2M Q4 '23: -7.2M Q1 '24: 15.9M Q2 '24: -4.2M Q3 '24: 58.9M Q4 '24: 52.8M Q1 '25: 31M Q2 '25: 52.7M Q3 '25: 39.7M Q4 '25: 77.5M Q1 '26: 80.4M Q2 '26: 74.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -28.2M Q4 '21: -61.8M Q1 '22: -32.7M Q2 '22: -59.6M Q3 '22: -33.7M Q4 '22: -27.5M Q1 '23: -31.5M Q2 '23: -37M Q3 '23: -23M Q4 '23: -9.1M Q1 '24: 14.6M Q2 '24: -5.3M Q3 '24: 57.8M Q4 '24: 52M Q1 '25: 24.8M Q2 '25: 50.8M Q3 '25: 38M Q4 '25: 75.4M Q1 '26: 73.2M Q2 '26: 71.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '20: 18.4M Q3 '20: 19.7M Q1 '21: 21.3M Q2 '21: 22.2M Q3 '21: 22.2M Q1 '22: 25.1M Q2 '22: 25.5M Q3 '22: 25.6M Q1 '23: 25.7M Q2 '23: 26.7M Q3 '23: 28.9M Q1 '24: 29.3M Q2 '24: 29.6M Q3 '24: 29.9M Q1 '25: 29.9M Q2 '25: 29.7M Q3 '25: 29.8M Q1 '26: 30.5M Q2 '26: 30.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -3.00 0.00 3.00 6.00 9.00 Q3 '21: -2.71 Q4 '21: -3.13 Q1 '22: -4.38 Q2 '22: -4.74 Q3 '22: -5.21 Q4 '22: -5.51 Q1 '23: -5.28 Q2 '23: -5.43 Q3 '23: -1.47 Q4 '23: 0.39 Q1 '24: 2.18 Q2 '24: 3.96 Q3 '24: 2.08 Q4 '24: 3.00 Q1 '25: 4.17 Q2 '25: 4.93 Q3 '25: 6.68 Q4 '25: 6.85 Q1 '26: 7.48 Q2 '26: 7.98 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for KRYS: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.